Elena Perin

Elena Perin


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Maurizio SabbatiniMaurizio Sabbatini
Maurizio Sabbatini
IZIlaria Zanellato
Ilaria Zanellato
Mauro RaveraMauro Ravera
Mauro Ravera
Elisabetta GabanoElisabetta Gabano
Elisabetta Gabano
EPElena Perin
Elena Perin
Domenico OsellaDomenico Osella
Domenico Osella

Verified
Journal Article
Open access
Mauro RaveraMauro Ravera
Mauro Ravera
IZIlaria Zanellato
Ilaria Zanellato
Elisabetta GabanoElisabetta Gabano
Elisabetta Gabano
EPElena Perin
Elena Perin
BRBeatrice Rangone
Beatrice Rangone
Domenico OsellaDomenico Osella
Domenico Osella
Cisplatin and several non-steroidal anti-inflammatory drugs (NSAIDs) have been proven to act synergistically or at least additively on several tumor cell lines. Dual-action cisplatin-based Pt(IV) combos containing ketoprofen and naproxen offer good antiproliferative performance on a panel of human tumor cell lines, including a malignant pleural mesothelioma (MPM) one, a very chemoresistant tumor. The main reason of the increased activity relies on the enhanced lipophilicity of these Pt(IV) conjugates that in turn promotes increased cellular accumulation. A quick Pt(IV)→Pt(II) reduction generates the active cisplatin metabolite. The NSAID adjuvant action seems to be almost independent from cyclooxygenase-2 (COX-2) expression in the tumor cells under investigation (lung A-549, colon HT-29, HCT 116, SW480, ovarian A2780, and biphasic MPM MSTO-211H), but it seems to rely (at least in part) on the activation of the NSAID activated gene, NAG-1 (a member of the transforming growth factor beta, TGF-β, superfamily), which has been suggested to be involved in NSAID antiproliferative activity.

15 April 2020 in JBIC Journal of Biological Inorganic Chemistry
Verified
Journal Article
Closed access
PDF file
DCDavide Corinti
Davide Corinti
MCMaria-Elisa Crestoni
Maria-Elisa Crestoni
SFSimonetta Fornarini
Simonetta Fornarini
EDEslam Dabbish
Eslam Dabbish
ESEmilia Sicilia
Emilia Sicilia
Domenico OsellaDomenico Osella
Domenico Osella

11 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Aldo ArraisAldo Arrais
Aldo Arrais
EBElisa Bona
Elisa Bona
Valeria TodeschiniValeria Todeschini
Valeria Todeschini
ACAlice Caramaschi
Alice Caramaschi
NMNadia Massa
Nadia Massa
VGValentina Gianotti
Valentina Gianotti
Antimicrobial resistance related to the misuse of antibiotics is a well-known current topic. Their excessive use in several fields has led to enormous selective pressure on pathogenic and commensal bacteria, driving the evolution of antimicrobial resistance genes with severe impacts on human health. Among all the possible strategies, a viable one could be the development of medical features that employ essential oils (EOs), complex natural mixtures extracted from different plant organs, rich in organic compounds showing, among others, antiseptic properties. In this work, green extracted essential oil of Thymus vulgaris was included in cyclic oligosaccharides cyclodextrins (CD) and prepared in the form of tablets. This essential oil has been shown to have a strong transversal efficacy both as an antifungal and as an antibacterial agent. Its inclusion allows its effective use because an extension of the exposure time to the active compounds is obtained and, therefore, a more marked efficacy, especially against biofilm-producing microorganisms such as P. aeruginosa and S. aureus, was registered. The efficacy of the tablet against candidiasis opens their possible use as a chewable tablet against oral candidiasis and as a vaginal tablet against vaginal candidiasis. Moreover, the registered wide efficacy is even more positive since the proposed approach can be defined as effective, safe, and green. In fact, the natural mixture of the essential oil is produced by the steam current method; therefore, the manufacturer employs substances that are not harmful, with very low production and management costs.

6 December 2018 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
Elisabetta GabanoElisabetta Gabano
Elisabetta Gabano
Mauro RaveraMauro Ravera
Mauro Ravera
EPElena Perin
Elena Perin
IZIlaria Zanellato
Ilaria Zanellato
BRB. Rangone
B. Rangone
Domenico OsellaDomenico Osella
Domenico Osella
Three pairs of asymmetric dicarboxylato derivatives based on the cisplatin and oxaliplatin-like skeletons have been synthesized de novo or re-synthesized. The axial ligands consist of one medium-chain fatty acid (MCFA), namely clofibrate (i.e. 2-(p-chlorophenoxy)-2-methylpropionic acid, CA), heptanoate (HA) or octanoate (OA), respectively, and an inactive acetato ligand that imparts acceptable water solubility to such conjugates. Stability tests provided evidence for the partial formation of two hydrolyzed products, corresponding to two monoaqua diastereomers derived from the substitution of an equatorial chlorido ligand with a water molecule. The complexes have been tested on three different colon cancer cell lines having different histological history, and also on the cisplatin-sensitive A2780 ovarian cancer cell line for comparison. This allowed the evaluation not only of the increase in activity on passing from Pt(II) to Pt(IV) derivatives, but also the selectivity towards colon cancer cells brought about by the cyclohexane-1R,2R-diamine carrier ligand.

12 July 2017 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
Elisabetta GabanoElisabetta Gabano
Elisabetta Gabano
EPElena Perin
Elena Perin
CFC. Fielden
C. Fielden
James PlattsJames Platts
James Platts
AGA. Gallina
A. Gallina
Mauro RaveraMauro Ravera
Mauro Ravera
Oxidation of [Pt(II)Cl(terpy)]+ (terpy = 2,2′:6′,2′′-terpyridine) has been attempted with several oxidizing agents and under different experimental conditions in order to obtain a Pt(IV) complex suitable for the conjugation to nanovectors to be used in drug delivery targeting for anticancer therapy. The best compromise in terms of yield and purity of the final complex was obtained by microwave-assisted reaction at 70 °C in 50% aqueous H2O2 for 2 h. Under these conditions the quantitative formation of [Pt(IV)Cl(OH)2(terpy)]+ was observed. The subsequent synthetic steps were, (i) functionalization of [Pt(IV)Cl(OH)2(terpy)]+ in the axial position with succinic anhydride to obtain [Pt(IV)Cl(OH)(succinato)(terpy)]+ and (ii) reaction of the latter with nonporous silica nanoparticles (SNPs) with an external shell containing primary amino groups to obtain a nanovector able to transport the Pt(IV) antitumor prodrug in the form of a conjugate Pt-SNP. Finally, the antiproliferative activity and cell accumulation of [Pt(II)Cl(terpy)]+, [Pt(IV)Cl(OH)2(terpy)]+, and the Pt-SNP conjugate were measured on three cancer cell lines. Despite highly effective accumulation of Pt-SNP in cells, a modest increase in activity was observed with respect to the molecular species. Further experiments showed that the Pt-SNP conjugate can release [Pt(II)Cl(terpy)]+ upon reduction, but this metabolite may undergo hydrolysis, and the resulting aquo complex could coordinate once again the free amino groups of the SNPs. In the resulting tetraamine form, the Pt(II) complex conjugated to the SNPs cannot completely perform its antiproliferative activity.